Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Behringer

Showing results (1171-1180 of 1,187) with videos related to

Pageof 119
Sort By:
The Lancet. Oncology|October 26, 2016
Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trialSalah-Eddin Al-Batran, Ralf D Hofheinz, Claudia Pauligk, et al.
Hematological Oncology|February 19, 2020
Baseline and interim PET-based outcome prediction in peripheral T-cell lymphoma: A subgroup analysis of the PETAL trialChristine Schmitz, Jan Rekowski, Stefan P Müller, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 12, 2018
Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas (PETAL): A Multicenter, Randomized Phase III TrialUlrich Dührsen, Stefan Müller, Bernd Hertenstein, et al.
Leukemia|October 3, 2018
Sequential high-dose cytarabine and mitoxantrone (S-HAM) versus standard double induction in acute myeloid leukemia-a phase 3 studyJan Braess, Susanne Amler, Karl-Anton Kreuzer, et al.
Lancet (London, England)|July 6, 2024
Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trialPeter Borchmann, Justin Ferdinandus, Gundolf Schneider, et al.
Annals of Hematology|January 6, 2019
Six versus eight doses of rituximab in patients with aggressive B cell lymphoma receiving six cycles of CHOP: results from the "Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas" (PETAL) trialAndreas Hüttmann, Jan Rekowski, Stefan P Müller, et al.
Development (Cambridge, England)|February 12, 2024
Pluripotency of a founding field: rebranding developmental biologyCrystal D Rogers, Chris Amemiya, Swathi Arur, et al.
Geburtshilfe Und Frauenheilkunde|April 23, 2026
Fertility Preservation for Patients with Malignant Disease. Guideline of the DGGG, OEGGG and SGGG (S2k-Level, AWMF Registry No. 015/082, May 2025)Laura Lotz, Sabine Kliesch, Dunja Baston-Buest, et al.
Haematologica|April 2, 2026
Outcomes of real-world complete responders after fixed-duration glofitamab in relapsed/refractory large B-cell lymphomaEvgenii Shumilov, Rebecca Wurm-Kuczera, Joseph Kauer, et al.
Geburtshilfe Und Frauenheilkunde|July 3, 2018
Fertility Preservation for Patients with Malignant Disease. Guideline of the DGGG, DGU and DGRM (S2k-Level, AWMF Registry No. 015/082, November 2017) - Recommendations and Statements for Girls and WomenRalf Dittrich, Sabine Kliesch, Andreas Schüring, et al.
Pageof 119

Showing results (1171-1180 of 1,187) with videos related to

Sort By:
Pageof 119
The Lancet. Oncology|October 26, 2016
Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trialSalah-Eddin Al-Batran, Ralf D Hofheinz, Claudia Pauligk, et al.
Hematological Oncology|February 19, 2020
Baseline and interim PET-based outcome prediction in peripheral T-cell lymphoma: A subgroup analysis of the PETAL trialChristine Schmitz, Jan Rekowski, Stefan P Müller, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 12, 2018
Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas (PETAL): A Multicenter, Randomized Phase III TrialUlrich Dührsen, Stefan Müller, Bernd Hertenstein, et al.
Leukemia|October 3, 2018
Sequential high-dose cytarabine and mitoxantrone (S-HAM) versus standard double induction in acute myeloid leukemia-a phase 3 studyJan Braess, Susanne Amler, Karl-Anton Kreuzer, et al.
Lancet (London, England)|July 6, 2024
Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trialPeter Borchmann, Justin Ferdinandus, Gundolf Schneider, et al.
Annals of Hematology|January 6, 2019
Six versus eight doses of rituximab in patients with aggressive B cell lymphoma receiving six cycles of CHOP: results from the "Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas" (PETAL) trialAndreas Hüttmann, Jan Rekowski, Stefan P Müller, et al.
Development (Cambridge, England)|February 12, 2024
Pluripotency of a founding field: rebranding developmental biologyCrystal D Rogers, Chris Amemiya, Swathi Arur, et al.
Geburtshilfe Und Frauenheilkunde|April 23, 2026
Fertility Preservation for Patients with Malignant Disease. Guideline of the DGGG, OEGGG and SGGG (S2k-Level, AWMF Registry No. 015/082, May 2025)Laura Lotz, Sabine Kliesch, Dunja Baston-Buest, et al.
Haematologica|April 2, 2026
Outcomes of real-world complete responders after fixed-duration glofitamab in relapsed/refractory large B-cell lymphomaEvgenii Shumilov, Rebecca Wurm-Kuczera, Joseph Kauer, et al.
Geburtshilfe Und Frauenheilkunde|July 3, 2018
Fertility Preservation for Patients with Malignant Disease. Guideline of the DGGG, DGU and DGRM (S2k-Level, AWMF Registry No. 015/082, November 2017) - Recommendations and Statements for Girls and WomenRalf Dittrich, Sabine Kliesch, Andreas Schüring, et al.
Pageof 119